Search Results

1 - 10 of 24 items :

  • Human Biology x
Clear All
Plerixafor for patients who fail cytokine-or chemotherapy-based stem cell mobilization: Results of a prospective study by the Polish Lymphoma Research Group (PLRG)

Background Autologous hematopoietic stem cell transplantation (autoHSCT) is widely applied for the treatment of patients with lymphoid malignancies [ 1 , 2 ]. Standard indications include multiple myeloma (MM), Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). While in MM autoHSCT is used as consolidation of first line treatment, for most of lymphoma subtypes it is considered after failure of initial chemotherapy. Currently, autoHSCT procedures are almost exclusively performed using peripheral blood as a source of stem cells, which requires successful

Open access
Stem Cell Transplantation in Pediatric Patients with Myelodysplastic Syndrome at a Single Institution

Introduction Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal stem cell disorders, characterized by ineffective hematopoiesis, a variable degree of cytopenia, and an increased risk for developing acute myelogenous leukemia (AML) [1]. MDS with ≥ 2% blasts in PB or ≥ 5% but less than 20% blasts in the BM is classified as MDS-EB in the most recent WHO classification of myeloid neoplasms [ 2 ]. The variant MDS-EB in transformation (MDS-EB-t) is retained in the pediatric classification of MDS, [ 3 ] and is characterized by a PB or BM blast

Open access
Selected factors influencing angiogenesis and hematopoietic niche

proangiogenic cytokines and miRNAs correspond with the activity of new vessels development. In neoplastic disorders, angiogenesis takes part in the dissemination of cancer cells and progression of the disease. The other spectrum of interest is the evaluation of proangiogenic factors in the context of their influence on the regeneration of hematopoiesis after damage caused by high dose chemotherapy and stem cells transplantation [ 7 ]. Bone marrow niche is a unique microenvironment containing growth factors, accessory cells, extracellular matrix proteins and cell

Open access
Nivolumab for relapsed/refractory classical Hodgkin lymphoma after brentuximab vedotin failure – Polish Lymphoma Research Group real-life experience

Introduction Despite the effective frontline treatment of classical Hodgkin lymphoma (cHL), about 10% of early-stage and 30% of advanced stage patients experience disease relapse or have refractory disease [ 1 ]. Only half of relapsed/refractory (R/R) patients can be cured with salvage chemotherapy followed by high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) [ 2 ]. For patients relapsing after second-line treatment, the possible effective therapy option can be salvage treatment with novel agents that have emerged in recent years

Open access
Prognostic value of soluble angiotensin II receptor 1 and soluble angiotensin converting enzyme (CD 143) in patients with acute leukemia

binds to either Ang II-type 1 receptors (AGTR1) or Ang II-type 2 receptors (AGTR2). The AGTR1 and AGTR2 can act as antagonists, and mediate effects on cell migration and proliferation of metastatic cancer cells and hemopoietic stem-progenitor cells [ 7 ]. Components of the RAS are frequently differentially expressed in various cancers in comparison with their corresponding non-malignant tissue. In particular, over-expression of AGTR1 [ 3 ]. Studies of knockout mice for ACE as well as other RAS components such as angiotensinogen, renin, AGTR1 and AGTR2 have further

Open access
Bankowanie. Mikrobiologiczne bezpieczeństwo przeszczepienia krwiotwórczych komórek macierzystych

. Hematopoietic stem and progenitur cell harvesting: technical advances and clinical utility. J Blood Med. 2015; 6: 55–67. Hequet O. Hematopoietic stem and progenitur cell harvesting: technical advances and clinical utility J Blood Med. 2015 6 55 67 [2] Demiriz IS, Tekgunduz E, Altuntas F. What is the most appropriate source for hematopoietic stem cell transplantation? Peripheral stem cell/bone marrow/cord blood. Bone Marrow Research, 2012; 1-5 Demiriz IS Tekgunduz E Altuntas F. What is the most appropriate source for hematopoietic stem cell transplantation? Peripheral stem

Open access
Opieka ginekologiczna po transplantacji komórek krwiotwórczych – zalecenia na podstawie piśmiennictwa i własnych doświadczeń

poszczególnych części manuskryptu, ocena i akceptacja całego tekstu. MD, MB, DW, JMZ – ocena i akceptacja całego tekstu. Conflict of interest Konflikt interesu/ Conflict of interest: Autorzy nie zgłaszają konfliktu interesu. Finansowanie/ Financial support Nie dotyczy. Etyka/Ethics Treści przedstawione w artykule są zgodne z zasadami Deklaracji Helsińskiej, dyrektywami EU oraz ujednoliconymi wymaganiami dla czasopism biomedycznych. Piśmiennictwo/References [1] Passweg JR, Baldomero H, Bader P, et al. Hematopoietic stem cell transplantation

Open access
Stan odżywienia chorych po transplantacji komórek krwiotwórczych

Intake and Nutritional Status by the Type of Hematopoietic Stem Cell Transplantation. Clin Nutr Res 2012;1(1):3. 10.7762/cnr.2012.1.1.3 So EJ Lee JS Kim JY Nutritional Intakeand Nutritional Status by the Type of Hematopoietic Stem Cell Transplantation Clin Nutr Res 2012 1 1 3 [3] Akbulut G. New perspective for nutritional support of cancer patients: Enteral/parenteral nutrition. Exp Ther Med 2011;2(4):675–84. 10.3892/etm.2011.247 Akbulut G New perspective for nutritional support of cancer patients: Enteral/parenteral nutrition Exp Ther Med

Open access
Postępowanie w chłoniakach z obwodowych limfocytów T i NK

wynosiło 62%. W czterech analizowanych badaniach porównywano chemioterapię w wysokich dawkach z leczeniem tradycyjnym. Ich podsumowanie nie wykazało istotnych korzyści ze stosowania leczenia zawierającego autologiczny przeszczep szpiku ( autologous stem cell transplant – ASCT). Nie zaobserwowano różnicy pomiędzy pacjentami przeszczepianymi w całkowitej i częściowej remisji. Nie ma dowodów na skuteczność przeszczepów autologicznych w nawrotowej postaci chłoniaków T-komórkowych. Fossard i wsp. analizowali dane pochodzące od 269 pacjentów z Francji, Belgii i Portugalii, w

Open access